Company Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Why Investors Should Care
Revenue has grown at a 30.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.51M (-90.6% YoY); net profit $-581.60M.
- Trailing 12 Months Year-on-year growth — revenue +68.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 30.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 30.40% |
| 1 Year: | 68.60% |
Stock Price Performance
| 1 Year: | -10.56% |
| 6 Months: | -6.28% |
| 3 Months: | -7.97% |
| 1 Month: | +0.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 30.4% over 5 years.
CONS
- Trading 34.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRSP CRISPR Therapeutics AG R2K | 50.46 | -8.18 | $4.97B | 0.00% | -31.41% | -31.21% | 30.40% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 328.00K | 318.00K | 211.93M | 77.02M | 157.00K | 44.00K | 148.00K | 370.00K | 539.00K | 900.70M | 824.00K | 940.00K | 158.00K | 94.00K | 100.00M | 70.00M | 0 | 504.00K | 517.00K | 602.00K | 865.00K | 892.00K | 889.00K | 1.46M |
| Operating Income | -3.74M | -3.62M | -6.20M | -12.17M | -11.65M | -16.56M | -14.61M | -25.31M | -20.74M | -21.31M | -23.57M | 972.00K | -27.00M | -37.29M | -49.43M | -45.23M | -48.42M | -54.98M | 139.16M | 10.98M | -73.59M | -80.69M | -92.40M | -107.76M | -114.54M | 762.62M | -128.85M | -175.97M | -183.26M | -182.39M | -64.49M | -95.22M | -132.41M | -140.59M | -151.26M | -110.13M | -148.42M | -229.32M | -132.06M | -130.25M |
| Net Income | -3.24M | -3.64M | -6.35M | -12.27M | -8.44M | -17.16M | -14.68M | 17.10M | -21.48M | -22.32M | -24.71M | 140.00K | -28.30M | -38.38M | -50.71M | -47.59M | -48.41M | -53.70M | 138.42M | 30.54M | -69.73M | -79.66M | -92.44M | -107.04M | -113.16M | 759.23M | -127.15M | -179.22M | -185.83M | -174.55M | -53.06M | -77.74M | -112.15M | -116.59M | -126.41M | -85.94M | -136.00M | -208.55M | -106.44M | -122.93M |
| Diluted EPS | - | - | - | - | -1.53 | -3.15 | -2.77 | 0.40 | -0.54 | -0.56 | -0.62 | 0.00 | -0.62 | -0.82 | -1.07 | -0.92 | -0.93 | -1.01 | 2.40 | 0.51 | -1.15 | -1.30 | -1.32 | -1.50 | -1.51 | 9.44 | -1.67 | -2.32 | -2.40 | -2.24 | -0.67 | -0.98 | -1.41 | -1.43 | -1.49 | -1.01 | -1.58 | -2.40 | -1.17 | -1.28 |
| R&D Expense | - | - | 3.75M | - | 6.01M | 8.60M | 12.05M | - | 14.80M | 17.12M | 17.84M | - | 19.52M | 25.63M | 39.82M | - | 33.82M | 39.53M | 57.25M | - | 54.19M | 59.38M | 71.01M | - | 70.62M | 82.33M | 83.50M | 118.25M | 123.22M | 116.62M | 99.94M | 101.56M | 90.70M | 76.17M | 80.17M | 82.16M | 72.48M | 69.89M | 58.90M | 68.57M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 247.00K | 5.16M | 41.00M | 3.12M | 289.59M | 719.00K | 914.96M | 1.20M | 371.21M | 37.31M | 3.51M |
| Operating Income | -6.63M | -25.73M | -68.13M | -64.65M | -158.94M | 46.74M | -354.44M | 373.53M | -673.16M | -222.54M | -466.57M | -664.57M |
| Net Income | -7.01M | -25.50M | -23.18M | -68.36M | -164.98M | 66.86M | -348.87M | 377.66M | -650.17M | -153.61M | -366.25M | -581.60M |
| Diluted EPS | - | - | - | -1.71 | -3.44 | 1.17 | -5.29 | 4.70 | -8.36 | -1.94 | -4.34 | -6.47 |
| R&D Expense | 1.51M | 12.57M | 42.24M | 69.80M | 113.77M | 179.36M | 221.38M | 340.57M | 461.64M | 387.33M | 310.24M | 284.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 159.42M | 344.96M | 271.35M | 489.02M | 1.07B | 1.83B | 2.75B | 2.24B | 2.23B | 2.24B | 2.27B |
| Total Equity | -581.00K | -6.97M | -29.10M | 232.85M | 187.83M | 392.19M | 939.42M | 1.66B | 2.40B | 1.88B | 1.88B | 1.93B | 1.92B |
| Cash & Equivalents | 361.00K | 945.00K | 155.96M | 315.52M | 239.76M | 456.65M | 943.77M | 1.17B | 923.03M | 211.88M | 389.48M | 298.26M | 347.56M |
| Total Liabilities | - | - | 124.03M | 112.12M | 83.51M | 96.82M | 127.33M | 163.73M | 352.42M | 367.58M | 346.77M | 309.95M | 343.43M |
| Current Liabilities | - | - | 10.15M | 22.00M | 14.51M | 27.75M | 57.11M | 94.26M | 119.88M | 121.11M | 108.79M | 87.78M | 149.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -52.86M | -70.09M | -96.24M | 56.68M | -238.37M | 538.97M | -495.74M | -260.38M | -142.77M | -345.01M |
| Investing Cash Flow | - | 31.88M | -8.31M | -2.77M | 1.32M | -541.17M | -1.04B | -258.65M | 374.65M | -280.48M | -31.80M |
| Financing Cash Flow | - | 183.22M | 2.61M | 315.93M | 430.98M | 1.02B | 250.94M | 38.59M | 62.66M | 331.98M | 426.03M |
| Capital Expenditure | -1.15M | -3.02M | -7.81M | -2.77M | -6.68M | -18.36M | -81.70M | -37.19M | -9.47M | -1.90M | -914.00K |
| Free Cash Flow | - | -55.88M | -77.91M | -99.01M | 49.99M | -256.72M | 457.27M | -532.93M | -269.85M | -144.68M | -345.93M |
| Share Buybacks | - | - | - | 57.00K | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -10,416.6% | -1,319.3% | -157.7% | -5,087.8% | 16.1% | -49,295.5% | 40.8% | -56,190.4% | -60.0% | -1,250.4% | -18,933.6% |
| Net Margin % | - | -10,325.1% | -448.8% | -166.7% | -5,281.1% | 23.1% | -48,520.9% | 41.3% | -54,271.7% | -41.4% | -981.5% | -16,569.8% |
| ROE % | 100.5% | 87.6% | -10.0% | -36.4% | -42.1% | 7.1% | -21.0% | 15.7% | -34.7% | -8.2% | -19.0% | -30.3% |
| ROCE % | - | -17.2% | -21.1% | -25.2% | -34.5% | 4.6% | -20.4% | 14.2% | -31.7% | -10.5% | -21.7% | -31.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 11.73% | 11.31M | $706.14M |
| 2 | Blackrock Inc. | 7.96% | 7.68M | $479.35M |
| 3 | Orbis Allan Gray Ltd | 6.33% | 6.11M | $381.11M |
| 4 | Capital World Investors | 4.90% | 4.73M | $294.91M |
| 5 | State Street Corporation | 4.13% | 3.98M | $248.57M |
| 6 | GSK plc | 3.34% | 3.22M | $201.02M |
| 7 | T. Rowe Price Investment Management, Inc. | 3.06% | 2.95M | $184.29M |
| 8 | Geode Capital Management, LLC | 2.46% | 2.38M | $148.37M |
| 9 | SR One Capital Management, LP | 2.11% | 2.04M | $127.25M |
| 10 | FMR, LLC | 2.03% | 1.95M | $122.00M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRSP
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNRGtVMU94em43S21neEFpRzZ5ZmZPSWQxeU1RdDNpOTBvOFJHMkdvekd5NmhBdFZ5OEpVdWhBbURraDNxV2lXVG1hYnozSTNuYnlDOEJOX0cxWGFTRTFDQlFZNGhaSlJvM2RRY1ZqYzNvcFNkd3c0c0hncnRJanBMaTM4Ukd6QXVPdXZvSE…
CRISPR Therapeutics (CRSP) Stock Forecast & Analyst Ratings - Moomoo
<a href="https://news.google.com/rss/articles/CBMinwNBVV95cUxPbWR4VjBLUHVBTEw0SFlaS1dRdUJ2aE5BZmQxUldmOHFuWlJEWktiZ21oWFBJZ2oxV19LdXZYZkdHeFNFZWs3RVpaV0lvUUdVOGdWRzR0QURpZHhtLUNHRmpGQjJoSy1SSkU4WklxMTdZSExCNF83MkhxYmRKOUI0clFOd3p1cHlZZWVnR2…
Canal Insurance CO Purchases New Stake in CRISPR Therapeutics AG $CRSP - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOS2RZWk82aTZSdWQ5TFRYRzBST3dPVE9IaHhSb1NENWlyUVJkM1pxOTFQc2RkbkNCc1lLOWhBam1QekIxdV9JUER4T0p3Y0s1VE9velRtdnZ0bGtkNGNtQ2dvYmZtOHhJNkNJR3h5c0p1TEhBbDVXT3UzR1pEal90aDdPTEFFdWdxWUNPWX…
3 Reasons to Buy CRISPR Therapeutics Stock - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPWi1mWjg4TzRWQjVkanFDQ2x5YzI0OFZpbWZsSVRHaDZsdzczX0hIalM4cU9xbHFjVkdJUXFCOXFsTUtFWDF2cVVMOXRlWElIRkxsU242LUFJck9JR29HbDJKTFhLcjdhTUJERlN3RVZ0VklNYXBvSG1YaE5zdnVUQlNlWDJjcU5HSjZtcW…
CRSP Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9DWGhEZEdGaFo4QS0wRk9ERko4bmFuVzNnM2E0LVN6MnRBYWZJU2ZJcG1SNE8xTnJieFhXZWZFMWVSM2VQTHBvUEJBVDR1NUVxYzdQSk9LZUdFd2g3cVR2MEVrZ2lIWTdFa00zenV3?oc=5" target="_blank">CRSP Technical Anal…
CRISPR Therapeutics(CRSP) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqgJBVV95cUxQVVJjdUZXckVTbXFKTGg0T3ROd3dHRm1TVXo0UEI4UUVkYzJUSWsxaDZUY1laNWRIWWsxWl9DN3ZmUmVsdFU5anQ2VFVIdzZ0UVRWNkpvN2xKMEZhUjNJSzA1Y2d5bGdKRXJrdjFDcWx2eTlucUVJMVRXUXpXaGtQalpmZXFBZzlOQ1BKVW…
CRSP — Frequently Asked Questions
What is the current share price of CRISPR Therapeutics AG (CRSP)?
As of 2026-07-14 21:23 PDT, CRISPR Therapeutics AG (CRSP) trades at $50.46 on NasdaqGM. Its 52-week range is $44.34 to $76.78.
What is the market capitalisation of CRSP?
CRISPR Therapeutics AG (CRSP) has a market capitalisation of $4.97B on NasdaqGM.
What is the P/E ratio of CRSP?
CRSP trades at a trailing price-to-earnings (P/E) ratio of -8.18. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.65.
What is the return on equity (ROE) of CRSP?
CRSP has a return on equity (ROE) of -31.21%. Its return on capital employed (ROCE) is -31.41%.
Is CRSP a good stock to buy?
This page provides a data-driven analysis of CRISPR Therapeutics AG (CRSP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.